These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10970739)

  • 1. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
    Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
    J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
    Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
    Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
    Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CD4 hinge region in GP120 utilization by immunoglobulin domain 1.
    Murray JL; Hu QX; Navenot JM; Peiper SC
    Biochem Biophys Res Commun; 2002 Mar; 292(2):449-55. PubMed ID: 11906183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    Labrosse B; Treboute C; Brelot A; Alizon M
    J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    Cormier EG; Dragic T
    J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates.
    Coetzer M; Cilliers T; Ping LH; Swanstrom R; Morris L
    Virology; 2006 Dec 5-20; 356(1-2):95-105. PubMed ID: 16942785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.
    Salzwedel K; Berger EA
    Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12794-9. PubMed ID: 11050186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity.
    Sterjovski J; Churchill MJ; Roche M; Ellett A; Farrugia W; Wesselingh SL; Cunningham AL; Ramsland PA; Gorry PR
    Virology; 2011 Feb; 410(2):418-28. PubMed ID: 21216423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein.
    Shimizu N; Haraguchi Y; Takeuchi Y; Soda Y; Kanbe K; Hoshino H
    Virology; 1999 Jul; 259(2):324-33. PubMed ID: 10388657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between productive HIV-1 infection of macrophages and CCR5 utilization.
    Hung CS; Pontow S; Ratner L
    Virology; 1999 Nov; 264(2):278-88. PubMed ID: 10562492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5.
    Isaka Y; Sato A; Miki S; Kawauchi S; Sakaida H; Hori T; Uchiyama T; Adachi A; Hayami M; Fujiwara T; Yoshie O
    Virology; 1999 Nov; 264(1):237-43. PubMed ID: 10544150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.